Last edition
News about "autoimmune diseases "
Antengene Advances ATG-201 Autoimmune Programme with Australian Phase I Trial Approval
Antengene’s ATG-201 moves into multinational clinical development after receiving Australian ethics approval and completing the TGA’s CTN process for a Phase I study targeting B cell-related autoimmune diseases.
Autoimmune Diseases | 26/08/2026 | By News Bureau
Estrella Doses First Patient in EB103 Dose-Expansion Trial for Relapsed/Refractory B-Cell NHL
Estrella Immunopharma advances its STARLIGHT-1 Phase I/II trial with the first patient dosed in the EB103 dose-expansion cohort, building on promising early efficacy in relapsed/refractory B-cell non-Hodgkin’s lymphoma.
Autoimmune Diseases | 28/07/2026 | By News Bureau
MHRA Approves Use of UK-Donor Plasma for Five Additional Life-Saving Medicines
The UK's Medicines and Healthcare products Regulatory Agency has approved the use of UK-donor plasma for producing five additional plasma-derived medicines after determining that the risk of variant Creutzfeldt-Jakob disease (vCJD) transmission is negligible. The decision is expected to improve the resilience of the UK's plasma medicine supply chain.
Autoimmune Diseases | 10/07/2026 | By News Bureau | 102
Rise in Autoimmune Diseases Reported Across Karnataka, Warn Experts
During Rheumatology Awareness Month, experts highlight increasing cases of autoimmune and rheumatology disorders in Bengaluru and smaller towns, stressing early diagnosis to prevent severe complications and delayed treatment outcomes.
Autoimmune Diseases | 21/04/2026 | By News Bureau | 135
Immutep Limited will discontinue the Phase III TACTI-004 trial of eftilagimod alfa in first-line Non-Small Cell Lung Cancer after an interim analysis by the monitoring committee found the study unlikely to meet endpoints.
Autoimmune Diseases | 16/03/2026 | By News Bureau | 141
Antengene Licenses ATG-201 to UCB in Deal Worth Up to USD 1.1 Billion for Autoimmune Disease Therapy
Antengene grants UCB exclusive global rights to develop and commercialise ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases, in a deal worth over USD 1.1 billion in milestones and royalties.
Autoimmune Diseases | 06/03/2026 | By News Bureau | 223
Roche's Fenebrutinib Shows Promise in Third Phase III MS Trial
Roche reported positive Phase III FENhance 1 results, with fenebrutinib reducing relapses by 51 percent in relapsing multiple sclerosis, consistent with prior FENhance 2 and FENtrepid data. The company plans regulatory submissions, positioning fenebrutinib as a potential first-in-class BTK inhibitor for relapsing and primary progressive MS.
Autoimmune Diseases | 02/03/2026 | By News Bureau | 230
Nektar Therapeutics and UCSF collaborate to study TNFR2 agonist NKTR-0165 in multiple sclerosis, aiming to explore its potential for neuroprotection and reduced neurodegeneration.
Autoimmune Diseases | 18/02/2026 | By News Bureau | 209
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
Autoimmune Diseases | 03/02/2026 | By News Bureau | 252
IN8bio Prices Private Placement of up to USD 40.2 Million
IN8bio has priced a private placement of up to USD 40.2 million, comprising USD 20.1 million upfront and a milestone-based additional USD 20.1 million, to advance its novel gamma-delta T cell engager INB-619 towards an IND application, extend its cash runway into the first half of 2027.
Autoimmune Diseases | 20/12/2025 | By News Bureau | 195
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy